Letter
Medicine, General & Internal
Aparna Sharma, Ranjit K. Sahoo, Atul Batra, Archie Bleyer, Toni K. Choueiri, Thomas Powles
Summary: Adding adjuvant pembrolizumab after nephrectomy can significantly improve disease-free survival in patients with renal-cell carcinoma, but there are concerns regarding the arbitrary duration of 12 months of adjuvant treatment. Many patients discontinued treatment due to adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Thomas Tabourin, Ugo Pinar, Jerome Parra, Christophe Vaessen, Charles-Karim Bensalah, Francois Audenet, Pierre Bigot, Cecile Champy, Jonathan Olivier, Franck Bruyere, Nicolas Doumerc, Philippe Paparel, Bastien Parier, Francois-Xavier Nouhaud, Xavier Durand, Herve Lang, Nicolas Branger, Jean-Alexandre Long, Matthieu Durand, Thibaut Waeckel, Thomas Charles, Olivier Cussenot, Evanguelos Xylinas, Romain Boissier, Ricky Tambwe, Jean-Jacques Patard, Jean-Christophe Bernhard, Morgan Roupret
Summary: Chromophobe morphotype was significantly associated with better RFS in RCC patients who underwent PN, while pT stage, Fuhrman group, and positive surgical margins were risk factors for recurrence.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Sumeyye Su, Shaya Akbarinejad, Leili Shahriyari
Summary: This study utilized digital cytometry to estimate the percentage of different immune cell types in 526 renal tumors, revealing that the most common immune cell types in clear cell renal cell carcinomas (ccRCC) tumors are CD8+ T-cells, macrophages, and CD4+ T-cells. Furthermore, unsupervised clustering analysis identified four distinct groups of ccRCC tumors based on the relative numbers of immune cells.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Andrew W. Silagy, Ritesh R. Kotecha, Stanley Weng, Arturo Holmes, Nirmish Singla, Roy Mano, Kyrollis Attalla, Kate L. Weiss, Renzo G. DiNatale, Sujata Patil, Jonathan A. Coleman, Robert J. Motzer, Paul Russo, Martin H. Voss, A. Ari Hakimi
Summary: The systemic responses to cytoreductive nephrectomy in the management of metastatic renal cell carcinoma are variable. Patients undergoing surgery had fewer modifiable IMDC risk factors, fewer metastases, and higher proportions of clear cell histology. An increase in IMDC risk factors at 6 weeks and 6 months post-surgery was associated with adverse overall survival.
Article
Oncology
Xu Hu, Yaohui Wang, Yanxiang Shao, Kang Wu, Yaxiong Tang, Shangqing Ren, Xiang Li
Summary: This study compared the outcomes of radical nephrectomy (RN) versus partial nephrectomy (PN) in patients with non-clear cell renal cell carcinoma (nccRCC). The results showed that PN was associated with better overall survival (OS) and cancer-specific survival (CSS) compared to RN. For patients with T1 nccRCC, PN may be the preferred option.
Article
Multidisciplinary Sciences
Wenhao Lin, Zhenggang Yang, Ling Yan, Jun Dai, Chen Fang, Yining Hao, Danfeng Xu, Jin Zhang, Juping Zhao
Summary: This study compared radical nephrectomy (RN) with partial nephrectomy (PN) in patients with cystic renal cell carcinoma (cRCC) using data from the SEER database and a Chinese retrospective cohort. The results showed that, after propensity score-matching (PSM), RN was associated with worse overall survival and cancer-specific survival compared to PN in cRCC patients.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Hana Studentova, Martina Spisarova, Andrea Kopova, Anezka Zemankova, Bohuslav Melichar, Vladimir Student
Summary: Cytoreductive nephrectomy has long been considered the standard of care for patients with metastatic renal cell carcinoma. However, with the rapid changes in systemic therapy, the importance of this procedure has been widely discussed and disputed. Currently, there is a lack of prospective data on cytoreductive nephrectomy in the immunotherapy era, and retrospective studies with small patient numbers are the main source of evidence. Nevertheless, an individualized approach can help identify patients who may benefit from surgery combined with systemic treatment.
Article
Oncology
Nienie Qi, Fangzheng Zhao, Xiaoxiao Liu, Wei Wei, Junqi Wang
Summary: This study evaluated the effect of preoperative wait time on the prognosis of patients with clinically localized renal cell carcinoma. Prolonged surgical wait time (> 90 days) does not influence survival in these patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
T. K. Choueiri, P. Tomczak, S. H. Park, B. Venugopal, T. Ferguson, Y. -H. Chang, J. Hajek, S. N. Symeonides, J. L. Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. B. Haas, P. Sawrycki, H. Gurney, C. Chevreau, B. Melichar, E. Kopyltsov, A. Alva, J. M. Burke, G. Doshi, D. Topart, S. Oudard, H. Hammers, H. Kitamura, J. Bedke, R. F. Perini, P. Zhang, K. Imai, J. Willemann-Rogerio, D. I. Quinn, T. Powles
Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiao Wu, Johannes Uhlig, Brian M. Shuch, Annemarie Uhlig, Hyun S. Kim
Summary: In this study, a cost-effectiveness analysis was performed to assess the benefits of partial nephrectomy (PN) and percutaneous cryoablation (PCA) for patients with cT1a renal cell carcinoma (RCC). The results suggest that PCA is more cost-effective than PN in the majority of scenarios, although the currently available evidence is of limited quality.
EUROPEAN RADIOLOGY
(2023)
Article
Cell Biology
Ziad Bakouny, Ananthan Sadagopan, Praful Ravi, Nebiyou Y. Metaferia, Jiao Li, Shatha AbuHammad, Stephen Tang, Thomas Denize, Emma R. Garner, Xin Gao, David A. Braun, Laure Hirsch, John A. Steinharter, Gabrielle Bouchard, Emily Walton, Destiny West, Chris Labaki, Shaan Dudani, Chun-Loo Gan, Vidyalakshmi Sethunath, Filipe L. F. Carvalho, Alma Imamovic, Cora Ricker, Natalie Vokes, Jackson Nyman, Jacob E. Berchuck, Jihye Park, Michelle S. Hirsch, Rizwan Haq, Gwo-Shu Mary Lee, Bradley A. McGregor, Steven L. Chang, Adam S. Feldman, Catherine J. Wu, David F. McDermott, Daniel Y. C. Heng, Sabina Signoretti, Eliezer M. Van Allen, Toni K. Choueiri, Srinivas R. Viswanathan
Summary: This study comprehensively defines the clinical and molecular features of translocation renal cell carcinoma (tRCC), a subtype of kidney cancer driven by MiT/TFE gene fusions. tRCCs mainly harbor MiT/TFE fusions and homozygous deletions at chromosome 9p21.3, and display a heightened NRF2-driven antioxidant response. Patients with tRCC treated with vascular endothelial growth factor receptor inhibitors (VEGFR-TKIs) have worse outcomes compared to those treated with immune checkpoint inhibitors (ICI). The study findings may inspire new therapeutic hypotheses for tRCC.
Article
Oncology
Yidan Lou, Kaibo Guo, Song Zheng
Summary: This report describes a rare case of renal cell carcinoma metastasis to the pancreas, with isolated pancreatic metastasis being even rarer. The patient responded well to surgery and systemic therapy, and showed no recurrence after 2 years. In conclusion, isolated pancreatic metastasis of renal cell carcinoma is a distinct subtype with unique clinical characteristics, which may be explained by underlying molecular mechanisms. Surgery and systemic therapy offer survival benefits to patients with isolated pancreatic metastasis, although recurrence should be closely monitored.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemical Research Methods
Yangjun Zhang, Xiaoliang Wu, Jingzhen Li, Kui Sun, Heng Li, Libin Yan, Chen Duan, Haoran Liu, Ke Chen, Zhangqun Ye, Mugen Liu, Hua Xu
Summary: Irregular splicing in renal cell carcinoma (RCC) is associated with tumor formation and progression. Alternative splicing can be useful for subtype classification, while splicing inefficiency is linked to advanced conditions and unfavorable overall survival in patients with RCC. Factors such as splice site strength, nucleotide content, and exon length may disrupt splicing balance in RCC, affecting cancer-associated pathways and immune responses.
BRIEFINGS IN BIOINFORMATICS
(2021)
Review
Urology & Nephrology
Takafumi Yanagisawa, Manuela Schmidinger, Tatsushi Kawada, Kensuke Bekku, Takahiro Kimura, Shahrokh F. Shariat
Summary: Immune checkpoint inhibitors have revolutionized the treatment of metastatic renal cell carcinoma. For patients responding well to initial therapy, delaying the surgical removal of the kidney may improve survival. More research is needed to determine the optimal timing of nephrectomy in the era of immune checkpoint inhibitors.
EUROPEAN UROLOGY FOCUS
(2023)
Article
Oncology
Justine Panian, Ava Saidian, Kevin Hakimi, Archana Ajmera, William J. Anderson, Pedro Barata, Stephanie Berg, Sabina Signoretti, Steven Lee Chang, Vincent D'Andrea, Daniel George, Hannah Dzimitrowicz, Talal El Zarif, Hamid Emamekhoo, Evan Gross, Deepak Kilari, Elaine Lam, Isabel Lashgari, Sarah Psutka, Grant P. Rauterkus, Ahmed Shabaik, Bicky Thapa, Luke Wang, Nicole Weise, Kendrick Yim, Tian Zhang, Ithaar Derweesh, Rana R. McKay
Summary: This study analyzed the pathological outcomes of advanced or metastatic renal cell carcinoma patients who received immunotherapy prior to cytoreductive nephrectomy. The results showed that cytoreductive nephrectomy after immunotherapy is effective, but further prospective studies are needed to evaluate its role in the era of immunotherapy.
Article
Oncology
Eddie Zhang, Karen J. Ruth, Mark K. Buyyounouski, Robert A. Price Jr, Robert G. Uzzo, Mark L. Sobczak, Alan Pollack, J. . Karen Wong, David Y. T. Chen, Mark A. Hallman, Richard E. Greenberg, Deborah Watkins-Bruner, Tahseen Al-Saleem, Eric M. Horwitz
Summary: This study aimed to compare the preservation of erectile function between limiting the doses delivered to the penile bulb and corporal bodies with intensity modulated radiation therapy (IMRT) and standard IMRT in men with prostate cancer. The results showed that there was no significant difference in the preservation of erectile function between the two treatment methods.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Laura Bukavina, Mohit Sindhani, Shreyas S. Joshi, Elizabeth Plimack, Andres Correa, Nicole Uzzo, Alexander Kutikov, Robert Uzzo
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Antoin Douglawi, Alireza Ghoreifi, Umberto Carbonara, Wesley Yip, Robert G. Uzzo, Vitaly Margulis, Matteo Ferro, Ottavio De Cobelli, Zhenjie Wu, Giuseppe Simone, Riccardo Mastroianni, Koon H. Rha, Daniel D. Eun, Adam C. Reese, James R. Porter, Ithaar Derweesh, Reza Mehrazin, Giuseppe Rosiello, Riccardo Tellini, Marcus Jamil, Alexander Kenigsberg, Jason M. Farrow, William P. Schrock, Giovanni Cacciamani, Abhishek Srivastava, Amit S. Bhattu, Alexandre Mottrie, Mark L. Gonzalgo, Chandru P. Sundaram, Firas Abdollah, Andrea Minervini, Riccardo Autorino, Hooman Djaladat
Summary: This study retrospectively analyzed data of UTUC patients who underwent RNU and found that VH was associated with increased risk of metastasis and death.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F. Correa, Diana E. Magee
Summary: This study evaluated the cost effectiveness of BCG compared to sequential gemcitabine-docetaxel in high-risk NMIBC patients. The results showed that gemcitabine-docetaxel had similar effectiveness but lower cost than BCG, making it a potential alternative as a first-line intravesical therapy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Marshall Strother, Robert N. Uzzo, Elizabeth Handorf, Robert G. Uzzo
Summary: The study aimed to validate the overflowing beer sign (OBS) for distinguishing between lipid-poor angiomyolipoma (AML) and renal cell carcinoma, and to determine whether it improves the detection of lipid-poor AML when added to the angular interface sign. The results showed that both OBS and angular interface sign were strongly associated with AML and had high specificity in the lipid-poor population. Using both signs together increased the sensitivity of AML detection without significantly reducing specificity.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Multidisciplinary Sciences
Nityam Rathi, Worapat Attawettayanon, Yosuke Yasuda, Kieran Lewis, Gustavo Roversi, Snehi Shah, Andrew Wood, Carlos Munoz-Lopez, Diego A. Palacios, Jianbo Li, Nour Abdallah, Jared P. Schober, Marshall Strother, Alexander Kutikov, Robert Uzzo, Christopher J. Weight, Mohamed Eltemamy, Venkatesh Krishnamurthi, Robert Abouassaly, Steven C. Campbell
Summary: Accurate prediction of NBGFR after RN is crucial for clinical management and patient counseling. Preoperative global GFR, SRF, and RFC are important factors for this prediction. In this study, the accuracy of three methods (NRS, software-derived PVA, and LWH measurements) for determining SRF and predicting NBGFR were compared. The results showed that software-derived PVA had the highest accuracy and precision in estimating SRF and predicting NBGFR.
SCIENTIFIC REPORTS
(2023)
Article
Urology & Nephrology
Jared P. Schober, Kevin B. Ginsburg, Alexander Kutikov, Eric Y. Cho, Matt Loecher, David Strauss, Alberto Andres Castro Bigalli, Elizabeth Handorf, Mengying Deng, Jordan Anaokar, David Y. T. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Andres F. Correa, Robert G. Uzzo, Marshall Strother
Summary: This study aimed to evaluate whether a simple point-of-care measurement system could be used to replace nuclear medicine renal scintigraphy (NMRS) in predicting estimated glomerular filtration rate (eGFR) after nephrectomy. The results showed that the point-of-care tool (RENAL-MS) performed equally well as NMRS in predicting postoperative eGFR and de novo Stage 3 chronic kidney disease (CKD), suggesting that NMRS may not be necessary in this setting.
Article
Urology & Nephrology
Deepak K. Pruthi, Gregor Miller, Donna P. Ankerst, Matthias Neumair, Umberto Capitanio, Andres F. Correa, Brian R. Lane, Eduard Roussel, Thomas B. Mcgregor, Ithaar H. Derweesh, Mauricio Cordeiro, Phillip M. Pierorazio, Carlos Calvo, Hai Bi, Sabrina L. Noyes, Margaret Meagher, Alexander Kutikov, Robert G. Uzzo, Hendrik Van Poppel, Alessandro Larcher, Francesco Montorsi, Michael W. Kattan, Dharam Kaushik, Michael A. Liss
Summary: This study aimed to investigate whether clinical risk factors and morphometric features on preoperative imaging can predict pathological upstaging in cT1 renal cell carcinoma patients. Through a retrospective study, we found that increasing preoperative tumor size, increasing age, diabetes, higher BMI, and male sex were associated with pathological upstaging. Additionally, hilar tumors were more likely to be upstaged.
JOURNAL OF UROLOGY
(2023)
Article
Medicine, General & Internal
Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr
Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.
Meeting Abstract
Urology & Nephrology
Laura Bukavina, Mohit Sindhani, Henkel Valentine, Daniel Ranti, Kirtishri Mishra, Alexander Kutikov, Shilpa Gupta, John Sfakianos, Mahmoud Ghannoum, Mauricio Retuerto, Andres Correa, Robert Uzzo, Philip Abbosh
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Clara Cerrato, Margaret F. Meagher, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp T. Beksac, Mimi Nguyen, Savio D. Pandolfo, Kevin Hakimi, Luke Wang, Andrea Minervini, Clayton Lau, Monish Aron, Daniel Eun, Alexandre Mottrie, Carmen Mir, Chandru Sundaram, Alessandro Antonelli, Jihad Kaouk, Ithaar H. Derweesh
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Clara Cerrato, Devin Patel, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp Tuna Beksac, Andrea Minervini, Alessandro Antonelli, Maria Angela Cerruto, Clayton Lau, Akbar Ashrafi, Daniel Eun, Alexandre Mottrie, Carmen Mir, Margaret F. Meagher, Dhruv Puri, Mimi Nguyen, Sohail Dhanji, Franklin Liu, Savio D. Pandolfo, Alexander Kutikov, Francesco Montorsi, Inderbir S. Gill, Chandru Sundaram, Jihad Kaouk, Ithaar H. Derweesh
Summary: This study compares the outcomes of robotic-assisted partial nephrectomy (RAPN) and minimally invasive radical nephrectomy (MIS-RN) for complex renal masses (CRM). The results indicate that RAPN is not associated with increased risk of complications or worsened oncological outcomes compared to MIS-RN, and may be preferred when clinically indicated.
WORLD JOURNAL OF UROLOGY
(2023)